Effect of a Single High Dose of Vitamin D3 on Hospital LOS in Patients with COVID-19

jamanetwork.com
effect-of-a-single-high-dose-of-vitamin-d3-on-hospital-los-in-patients-with-covid-19

Among hospitalized patients with COVID-19, a single high dose of vitamin D3, compared with placebo, did not significantly reduce hospital length of stay. The findings do not support the use of a high dose of vitamin D3 for treatment of moderate to severe COVID-19.

Of 240 randomized patients, 237 were included in the primary analysis (mean [SD] age, 56.2 [14.4] years; 104 [43.9%] women; mean [SD] baseline 25-hydroxyvitamin D level, 20.9 [9.2] ng/mL).

Median (interquartile range) length of stay was not significantly different between the vitamin D3 (7.0 [4.0-10.0] days) and placebo groups (7.0 [5.0-13.0] days) (log-rank Pā€‰=ā€‰.59; unadjusted hazard ratio for hospital discharge, 1.07 [95% CI, 0.82-1.39]; Pā€‰=ā€‰.62).

The primary outcome was length of stay, defined as the time from the date of randomization to hospital discharge.

Read More